Abstracts tagged "Pulmonary Involvement and systemic sclerosis"

Abstract Number: 1722 • 2018 ACR/ARHP Annual Meeting
Patient-Level Factors Associated with Hospital Readmission Among Patients with Systemic Sclerosis Associated Pulmonary Hypertension
Kimberly Showalter¹, Laura Pinheiro², Jackie Szymonifka³, Irina Sobol⁴, Virginia D. Steen⁵ and Jessica K. Gordon¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Internal Medicine, Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Cardiology, Weill Cornell Medicine, New York, NY, ⁵Rheumatology, MedStar Georgetown University Hospital, Washington, DC
Background/Purpose: Repeat hospitalizations in patients with pulmonary hypertension from all causes are associated with worse survival. However, predictors of systemic sclerosis associated pulmonary hypertension (SSc-PH)…
Abstract Number: 1685 • 2017 ACR/ARHP Annual Meeting
Factors Associated with the 6-Minute Walk Distance in Patients with Systemic Sclerosis
Sébastien Sanges¹, Jonathan Giovannelli², Vincent Sobanski³, Céline Podevin², Sandrine Dubois-Morell², Hélène Maillard⁴, Marc Lambert⁴, Nicolas Lamblin⁵, Pascal De Groote⁵, Jean-François Bervar⁶, Pierre-Yves Hatron⁷, Eric Hachulla⁸ and David Launay⁹, ¹Université Lille Nord de France, Faculté de Médecine Henri Warembourg, Lille, Lille, France, ²Service de Médecine Interne, Centre National de Référence de la Sclérodermie Sytémique, Lille, France, ³Univ. Lille, U995, Lille Inflammation Research International Center (LIRIC), F-59000 Lille, France, ⁴Department of internal medecine, Hôpital Claude Huriez, CHRU Lille, France, Lille, France, ⁵Service de Cardiologie, Lille, France, ⁶Service de Pneumologie, Lille, France, ⁷Univ Lille, CHU Lille, F-59000 Lille, France, Lille, France, ⁸CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, ⁹Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France
Background/Purpose: To assess the associations between the 6-minute walk distance (6MWD) and various disease parameters in patients with systemic sclerosis (SSc). Methods: Consecutive patients followed…
Abstract Number: 1902 • 2016 ACR/ARHP Annual Meeting
Detecting the Pulmonary Vascular Involvement and the Changes in Gene Activation Profiles at Early Stage of Systemic Sclerosis in Patients with Raynaud Phenomenon
Yoshinobu Koyama¹, Soichiro Fuke², Yoshiharu Sato³ and Toshie Higuchi⁴, ¹Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan, ²Department of Cardiology, Japan Red Cross Okayama Hospital, Okayama, Japan, ³DNA Chip Research Inc, Yokohama, Japan, ⁴Center for Autoimmune Diseases, Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan
Background/Purpose: Raynaud phenomenon (RP) is known to precede other disease manifestations of systemic sclerosis (SSc), and classically viewed as reversible vasospasm due to functional changes…
Abstract Number: 1901 • 2016 ACR/ARHP Annual Meeting
Screening for Pulmonary Arterial Hypertension in an Unselected Prospective Systemic Sclerosis Cohort
Els Vandecasteele¹, Benny Drieghe², Karin Melsens³, Kristof Thevissen², Michel De Pauw⁴, Ellen Deschepper⁵, Saskia Decuman⁵, Karolien Bonroy², Yves Piette⁶, Filip De Keyser⁵, Guy Brusselle² and Vanessa Smith², ¹Dep ofCcardiology, University Hospital Ghent, Ghent, Belgium, ²University Hospital Ghent, Ghent, Belgium, ³Department of Internal Medicine, Ghent University, Ghent, Belgium, ⁴Dep of cardiology, University Hospital Ghent, Ghent, Belgium, ⁵Ghent University, Ghent, Belgium, ⁶Dep of Rheumatology, University Hospital Ghent, Ghent, Belgium
Background/Purpose: Screening for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) improves outcome. The DETECT screening algorithm (DETECT-algorithm) is recommended in a high-risk SSc subgroup.…
Abstract Number: 2592 • 2013 ACR/ARHP Annual Meeting
Clinical Significance Of Endothelial Vasodilator Function Evaluated By Endopat In Patients With Systemic Sclerosis
Naohiko Aozasa¹, Yoshihide Asano¹, Masaru Hatano², Ryosuke Saigusa¹, Kouta Takakuwa¹, Takehiro Takahashi¹, Tetsuo Toyama¹, Hayakazu Sumida¹, Atsushi Yao³, Koichiro Kinugawa⁴, Hisataka Maki², Toshiro Inaba², Hironori Muraoka², Shun Minatsuki², Issei Komuro² and Shinichi Sato¹, ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ³Division for Health Service Promotion, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁴Department of Therapeutic strategy for heart failure, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by initial vascular injuries and resultant fibrosis of skin and certain internal organs. Evidence has…
Abstract Number: 2558 • 2013 ACR/ARHP Annual Meeting
Bone Morphogenic Protein Receptor 2 (BMPR2) Gene Mutations Are Associated To The Development Of Isolated Pulmonary Arterial Hypertension (PAH) In Systemic Sclerosis (SSc) Patients
Tatiana Sofia Rodriguez-Reyna¹, Jose Luis Hernandez-Oropeza², Tomas Rene Pulido-Zamudio³, Felipe Massó⁴, Jessica Gutierrez-Manjarrez¹, Alexandra Rueda de Leon-Aguirre¹, Julio Sandoval-Zarate³ and Carlos Rodriguez-Osorio⁵, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²Pulmonary Circulation Clinic, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ³Pulmonary Circulation Clinic, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁴Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁵Intensive Care Unit, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Background/Purpose: Isolated pulmonary arterial hypertension (PAH) secondary to Systemic Sclerosis (SSc) is a severe life-threatening complication. Several pathogenic pathways have been implicated in its development.…
Abstract Number: 1744 • 2013 ACR/ARHP Annual Meeting
Identifying Trajectories of Lung Function Change Over Time in Scleroderma
Ada Man¹, Todd Davidyock², Laura Western³, Michael Ieong², Yuqing Zhang⁴ and Robert W. Simms¹, ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³University of Maryland, Baltimore, MD, ⁴Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of scleroderma (SSc) mortality, yet little is known about how changes in lung function over time…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].